Getting historic dossiers registered in new markets can have its difficulties, especially when the dossier might have been developed before the development of current guidance and requirements. One such difficulty is the concept of Pharmaceutical Development and Quality by Design (QbD). Acorn Regulatory Project Manager Janet Fitzgerald looks at QbD in this article and how it can be used in developing historic dossiers.